effective, but the authors did not think DTPA suitable for long term use. It is already established that these preparations can be life saving in acute iron poisoning,3, 5, 12, 18 and~e stlin's important review to be published in this journal re-emphasizes that point.,--With chronic iron overload the results have been less spectacular. First reports in this connection came from Nloeschlin et al. 8 (deferoxamine) and Fahey,et al. 1 (DTPA) . In children these agents have been used chiefly in thalassemia when much iron has accumulated from numerous blood transfusions. Most physicians space the latter as far apart as possible to keep the iron intake low, though VV olman 19 suggested that keeping the hemoglobin level high by frequent transfusions would lessen the demand for exogenous iron which he thought would be no less toxic than hemoglobin iron. In any event, reduction of food iron is probably desirable in order to keep down iron absorption from the gastro-intestinal tract. 13 But in spite of all this an excessive amount of iron does accumulate in the body and it is to try to keep this within managable proportions that chelating agents have been used.
Deferoxamine combines with the trivalent iron free in the plasma and body fluids to form ferrioxamine. This in turn is rapidly excreted in the urine which becomes. deep orange in color when iron is present i n ap-preciable amounts. Iron is probably removed from the body stores rather than from transferrin and none is taken from hemoglobin.6 When DTPA is used it is thought that calcium is exchanged for iron at storage sites and the iron chelate thus formed is excreted in the urine., As with deferoxamine, elimination is rapid.15 Neither preparation has much effect on iron excretion in normal subjects. Inasmuch as these chelating agents are not effectively absorbed from the gastro-intestinal tract, both must be given parenterally. Deferoxamine, a white powder, is soluble in water (1 Gm. in 2 ml.) and is usually given by intramuscular injection, which the patients state is not particularly painful DTPA, on the other hand, often gives rise to pain if given intramuscularly and is best administered intravenously. It comes in a 25 per cent solution, each 4 ml. vial containing 1 Gm.
DTPA.
In moderate doses deferoxamine appears to be nontoxic, although Whitten How effective are these chelating agents? Their efficacy appears to be related to the amount of stored iron. If this is small in amount, they are comparatively ineffective, but when iron overload is heavy, with high plasma saturation, urinary output of iron can be considerably increased. Under the latter conditions there are reports '~~ 9, 13 of 24-hour urinary iron excretion in children with thalassemia of over 25 mg./Gm. deferoxamine, with individual 24-hour output of over 50 mg. in some instances. The usual range, however, is about 5-20 mg. daily.
There are fewer reports on DTPA in children, but Sephton Smith 14 has recorded an iron output up to 50 mg./Gm. One to 3 Gm. deferoxamine, depending on the size of the child, has been given intramuscularly daily to children in hospital, but for outpatient or home treatment it is not feasible to give more than 0.5 or possibly 1 Gm. per day. When a parent gives the injection the subcutaneous route may be used, and some children complain of pain. One ml. (0.5 Gm.) is as much as can reasonably be given and even this depends greatly upon the cooperation and reliability of parents. As treatment must continue more or less indefinitely, some rest periods are desirable and a scheme of four to five injections weekly may be followed.
Despite its disadvantages, the occasional use of DTPA will bring about the elimination of a worthwhile amount of iron without harming the patient, and if given only at the time of blood transfusion, a suf~cient interval will elapse between doses to obviate the risk of untoward effects. It may be given up to 150 mg./Kg. at a rate of not more than 20 mg./Kg./hour, 0.5 to I Gm. being added to 100 ml. of diluent. The latter can be the blood used for transfusion or other fluid such as 5 per cent dextrose water. The combination of DTPA used in this way with deferoxamine given intramuscularly in the interval between transfusions was suggested by Sephton Smith 14 and seems a reasonable method . of ther apy4 ' Is this prolonged and costly form of treatment really worthwhile? The answer seems to depend to a great extent on the frequency of blood transfusion and the consequent amount of iron taken in by the body. It will be remembered that a pint of blood contains about 250 mg. iron. In order to keep pace with the intake an equal amount must be eliminated before any inroads on stored iron can take place. This is quite apart from the iron taken into the body as food, some of which will be absorbed. Walsh and Gillick 16 thought that chelation therapy was well worth while if, following a test dose of deferoxamine, at least 10 mg. iron was excreted. We would agree with this view. There is, regrettably, no alternative method available at present to relieve these unfortunate children of excess iron.
What is needed is a non-toxic chelating agent, specific for iron, which is effective when given by mouth. This would make home treatment very much easier and the children would only need to attend hospital for blood transfusions. On those occasions an intravenous dose of DTPA or deferoxamine could judiciously be given as a supplement. This would be a real advance in the therapy of a child with chronic iron overload.
